Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising radioactive therapy for childhood cancer tested, but trial stopped early

NCT ID NCT04023331

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 29 times

Summary

This study tested a radioactive drug called 67Cu-SARTATE in 21 children with high-risk neuroblastoma, a serious nerve cancer. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, so results are limited, but it aimed to control the disease rather than cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Centre

    Cincinnati, Ohio, 45229, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Phoenix Children's Hospital

    Phoenix, Arizona, 85016, United States

  • University of Texas Southwestern Medical Centre

    Dallas, Texas, 75390, United States

  • University of Wisconsin

    Madison, Wisconsin, 53792, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.